Viridian's Veligrotug Nears a June 30 FDA Decision for Thyroid Eye Disease, Pitching a Five-Infusion Course Against Tepezza
An FDA decision on Viridian's IGF-1R antibody veligrotug is due June 30, 2026, after Phase 3 trials hit their endpoints in both active and chronic thyroid eye disease.